Leukotriene B4 receptor · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Leukotriene B4 receptor shows late clinical disease relevance led by bullous pemphigoid. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q9NPC1. Start with bullous pemphigoid, then reuse UniProt Q9NPC1 as the stable protein anchor across project notes and exports.
Start with bullous pemphigoid, then reuse UniProt Q9NPC1 as the stable protein anchor across project notes and exports.
Leukotriene B4 receptor shows late clinical disease relevance led by bullous pemphigoid. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with bullous pemphigoid because it currently carries late clinical support. Linked drugs include NOMACOPAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyLeukotriene B4 receptor 2
Review this target as Leukotriene B4 receptor, mapped to UniProt Q9NPC1. ChEMBL maps the protein component as Leukotriene B4 receptor 2. Sequence length is 358 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Leukotriene B4 receptor as ChEMBL target CHEMBL2095160, mapped to UniProt Q9NPC1. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Leukotriene B4 receptor is the right protein anchor across sources, using UniProt Q9NPC1 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why bullous pemphigoid is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Leukotriene B4 receptor |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | Q9NPC1 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Leukotriene B4 receptor 2 |
| UniProt Accession | Q9NPC1 |
| Component Type | Protein |
| Sequence Length | 358 aa |
Leukotriene B4 receptor 2
Review this target as Leukotriene B4 receptor, mapped to UniProt Q9NPC1. ChEMBL maps the protein component as Leukotriene B4 receptor 2. Sequence length is 358 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Leukotriene B4 receptor shows late clinical disease relevance led by bullous pemphigoid. 2 more disease programs remain visible in the same review block.
Start review with bullous pemphigoid because it currently carries late clinical support. Linked drugs include NOMACOPAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL292782 | 10.4 | Ki | 0.04 | Preclinical |
| CHEMBL340460 | 9.96 | Ki | 0.11 | Preclinical |
| CHEMBL65061 | 9.92 | Ki | 0.12 | Preclinical |
| CHEMBL328712 | 9.44 | IC50 | 0.36 | Preclinical |
| CHEMBL125723 | 9.35 | IC50 | 0.45 | Preclinical |
| CHEMBL125646 | 9.24 | IC50 | 0.58 | Preclinical |
| CHEMBL126200 | 9.22 | IC50 | 0.6 | Preclinical |
| CHEMBL136700 | 9.15 | Ki | 0.71 | Preclinical |
| CHEMBL125214 | 9.1 | IC50 | 0.8 | Preclinical |
| CHEMBL125559 | 9.0 | IC50 | 1.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein format | 16 | 183 | 7.6 |
| cell-based format | 6 | 9 | 6.6 |
| tissue-based format | 5 | 130 | 7.3 |
| cell membrane format | 2 | 21 | 6.4 |
| assay format | 1 | 17 | 5.8 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 15 | 124 | 6.8 |
| cell membrane format | 2 | 15 | 7.5 |
| organism-based format | 2 | 0 | — |
| tissue-based format | 1 | 11 | 6.1 |